Dr. Milind Desai discusses the design and results of the VALOR-HCM trial, which demonstrated that mavacamten reduced the need for septal reduction therapy at 16 weeks in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
advertisement
Cardiac Myosin Inhibitor Reduces Need for Septal Reduction Therapy in Obstructive HCM
Share
Save
Restart
Resume
Transcript
Cardiac Myosin Inhibitor Reduces Need for Septal Reduction Therapy in Obstructive HCM
closeShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Recommended
Details
Overview
Dr. Milind Desai discusses the design and results of the VALOR-HCM trial, which demonstrated that mavacamten reduced the need for septal reduction therapy at 16 weeks in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?